Ultragenyx Pharmaceutical financials
$15.32+6.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214.0M | $136.0M | $207.3M | $159.9M | $167.0M | $139.0M | $164.6M | $139.5M | $147.0M | $108.8M | $127.4M | $98.1M |
| Gross profit | $180.0M | $106.0M | $177.9M | $131.9M | $144.0M | $110.0M | $147.5M | $118.5M | $125.7M | $91.3M | $115.3M | $87.1M |
| Gross margin | 84.1% | 77.9% | 85.8% | 82.5% | 86.2% | 79.1% | 89.6% | 84.9% | 85.5% | 83.9% | 90.5% | 88.8% |
| Operating income | -$75.0M | -$169.0M | -$113.3M | -$170.9M | -$108.0M | -$143.0M | -$122.3M | -$132.0M | -$116.4M | -$165.3M | -$122.0M | -$145.1M |
| Net income | -$92.0M | -$185.0M | -$128.6M | -$180.4M | -$115.0M | -$151.0M | -$133.2M | -$133.5M | -$131.6M | -$170.7M | -$123.2M | -$159.6M |
| Net margin | −43.0% | −136.0% | −62.0% | −112.8% | −68.9% | −108.6% | −80.9% | −95.7% | −89.5% | −156.8% | −96.7% | −162.8% |
| Diluted EPS | $-0.90 | $-1.84 | $-1.29 | $-1.81 | $-1.17 | $-1.57 | $-1.39 | $-1.40 | $-1.52 | $-2.03 | $-1.52 | $-2.23 |
| EBITDA | -$67.0M | -$161.0M | -$104.5M | -$162.3M | -$99.0M | -$134.0M | -$112.8M | -$123.2M | -$107.5M | -$156.5M | -$122.0M | -$137.9M |
| Operating cash flow | -$97.0M | -$197.0M | -$99.8M | -$91.4M | -$109.0M | -$166.0M | -$79.3M | -$67.0M | -$77.0M | -$190.7M | -$83.9M | -$117.9M |
| Free cash flow | -$98.0M | -$198.0M | -$100.8M | -$92.7M | -$112.0M | -$167.0M | -$79.5M | -$68.6M | -$79.0M | -$193.9M | -$85.5M | -$121.6M |
| Diluted shares | 101.9M | 100.6M | 99.8M | 99.8M | 98.5M | 96.3M | 95.6M | 95.5M | 86.6M | 84.3M | 81.1M | 71.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.0M | $175.0M | $421.0M | $202.5M | $176.3M | $127.1M |
| Short-term investments | $167.0M | $238.0M | $259.0M | $222.7M | $311.3M | $367.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.26B | $1.30B | $1.53B | $1.19B | $1.31B | $1.31B |
| Total liabilities | $1.55B | $1.52B | $1.60B | $1.17B | $1.15B | $1.16B |
| Shareholders' equity | -$284.0M | -$236.0M | -$73.0M | $9.2M | $151.3M | $144.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology